Latest Earnings Results: Q2 '26
Estimated EPS
-$1.39
Reported EPS
-$1.46
Surprise
-5.32%
Estimated Rev
$6.53M
Reported Rev
$6.62M
Surprise
+1.41%
• Reported GAAP EPS of -$4.12 up 40.80% YoY • Reported revenue of $6.62M up 15.71% YoY • Lifeward expects its revenue momentum to continue in the second half of 2026, supported by a strong sales pipeline for the Company's portfolio of commercialized neurorehabilitation products and biomedical pipeline.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.79 | -- | -- | N/A |
Q2 '26 | -$1.39 | -$1.46 | -5.32% | MISSED |
Q1 '26 | -$1.18 | -$3.13 | -165.25% | MISSED |
Q4 '25 | -$0.96 | -$2.85 | -196.87% | MISSED |
Q3 '25 | -$0.20 | -$2.28 | -1040.00% | MISSED |